// App-Quantinova.ai

Filters

Biomarkers

No records found for your search

Conference Name

No records found for your search

Country

























Company

Search valid company name..

Conference Year













Drug











Disease

Medical Centers

Search valid medical center name..

Outcomes





Presenter

Search valid presenter name..

Principal Investigators

Search valid principal investigator name..

Phase










Patient Segments

Search valid patient segment..

Result



Sponsor

Search valid sponsor name..

Study ID

Search your valid Study ID..

Therapeutic Area
























45280 Abstracts

EXTERNAL VALIDATION OF THE OAKLAND SCORE IN 38,067 PATIENTS WITH ACUTE LOWER GASTROINTESTINAL BLEEDING

Kathryn Oakland - Digestive Disease Week (DDW) , 2020

Therapeutic Area

Disease

Drug/Treatment

Gastroenterology (GU)

Gastrointestinal bleeding

Hemostatic Solution

RAMAN SPECTROSCOPY DEMONSTRATES BIOMOLECULAR CHANGES AND PREDICTS RESPONSE TO BIOLOGICAL THERAPY IN INFLAMMATORY BOWEL DISEASE

Samuel C. Smith - Digestive Disease Week (DDW) , 2020

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Inflammatory bowel disease

N/A

REPRODUCIBILITY OF PICASSO SCORE BY USING NARROW BANDING IMAGES (NBI) TO ASSESS MUCOSAL AND HISTOLOGICAL HEALING IN ULCERATIVE COLITIS (UC) PATIENTS

Rosanna Cannatelli - Digestive Disease Week (DDW) , 2020

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Ulcerative colitis

N/A

OPTICAL ENHANCEMENT AND PROBE CONFOCAL LASER ENDOMICROSCOPY CAN ACCURATELY PREDICT RESPONSE TO BIOLOGICAL THERAPY IN INFLAMMATORY BOWEL DISEASE PATIENTS

Marietta Iacucci - Digestive Disease Week (DDW) , 2020

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Inflammatory bowel disease

Fluorescein sodium

ENDOSCOPIC MANAGEMENT OF BLUNT PANCREATIC TRAUMA IN CHILDREN: A RETROSPECTIVE SERIES FROM A LARGE HPB CENTRE

Taimur T. Shafi - Digestive Disease Week (DDW) , 2020

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Trauma

N/A

THE PEDIATRIC ENDOSCOPY PRACTICE IN EUROPE: PRELIMINARY RESULTS OF A WEB-BASED SURVEY ON BEHALF OF THE ENDOSCOPY SPECIAL INTEREST GROUP OF EUROPEAN SOCIETY OF GASTROENTEROLOGY, HEPATOLOGY AND NUTRITION (ESPGHAN)

Salvatore Oliva - Digestive Disease Week (DDW) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

ROLE OF ERCP IN THE DIAGNOSIS OF BILIARY ATRESIA: A RETROSPECTIVE SERIES FROM A LARGE HPB CENTRE

Taimur T. Shafi - Digestive Disease Week (DDW) , 2020

Therapeutic Area

Disease

Drug/Treatment

Gastroenterology (GU)

Biliary atresia

N/A

OUTCOMES FROM THE UK PURASTAT REGISTRY – A MULTICENTRE PROSPECTIVE OBSERVATIONAL STUDY TO EVALUATE THE ROLE OF PURASTAT IN THE MANAGEMENT OF GASTROINTESTINAL BLEEDING (POPS)

Sophie Arndtz - Digestive Disease Week (DDW) , 2020

Therapeutic Area

Disease

Drug/Treatment

Gastroenterology (GU)

Gastrointestinal bleeding

N/A

UN-TUTORED TRAINING PATHWAY TO ACHIEVE COMPETENCE IN ESOPHAGO-GASTRIC ENDOSCOPIC SUBMUCOSAL DISSECTION IN A WESTERN CENTRE

Massimiliano Di Pietro - Digestive Disease Week (DDW) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Esophageal squamous carcinoma cell

N/A

ASSOCIATION OF PATIENT FACTORS WITH PEDUNCOLATED AND NON-PEDUNCOLATED LESION REPORTING: OBSERVATIONS FROM THE EUROPEAN COLONOSCOPY QUALITY INVESTIGATION QUESTIONNAIRE

Anastasios Koulaouzidis - Digestive Disease Week (DDW) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

ENDOSCOPIC MANAGEMENT OF NON-DIMINUTIVE POLYPS: OBSERVATIONS FROM THE EUROPEAN COLONOSCOPY QUALITY INVESTIGATION QUESTIONNAIRE

Pedro Amaro - Digestive Disease Week (DDW) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

ASSOCIATION OF ASPECTS OF PROCEDURE WITH REPORTING OF FLAT AND PROTRUDED LESIONS: OBSERVATIONS FROM THE EUROPEAN COLONOSCOPY QUALITY INVESTIGATION QUESTIONNAIRE

Akiko Ono - Digestive Disease Week (DDW) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

TRANSFUSION INDEPENDENCE IS ASSOCIATED WITH IMPROVED OVERALL SURVIVAL IN MYELOFIBROSIS PATIENTS RECEIVING MOMELOTINIB

Ruben Mesa - European Hematology Association (EHA) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Myelofibrosis

Momelotinib

POMALIDOMIDE, BORTEZOMIB, AND DEXAMETHASONE AFTER 1 PRIOR LINE OF THERAPY IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA: A SAFETY SUBANALYSIS OF THE PHASE 3 OPTIMISMM TRIAL

Katja Weisel - European Hematology Association (EHA) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Multiple Myeloma

Dexamethasone

MOSUNETUZUMAB (MOSUN) MONOTHERAPY FOR ELDERLY/UNFIT PATIENTS (PTS) WITH FIRST-LINE DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) CONTINUES TO SHOW PROMISING SAFETY AND EFFICACY WITH DURABLE COMPLETE RESPONSES

Adam Olszewski - European Hematology Association (EHA) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Diffuse large B-cell lymphoma

Vincristine

EARLY SAFETY AND EFFICACY FINDINGS OF AUTO1 (CAT19), A FAST-OFF RATE CD19 CAR, IN RELAPSED /REFRACTORY INDOLENT B CELL LYMPHOMAS

Claire Roddie - European Hematology Association (EHA) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

B cell lymphomas

Cyclophosphamide

PIRTOBRUTINIB (LOXO-305), A NEXT GENERATION, HIGHLY SELECTIVE, NON-COVALENT BTK INHIBITOR IN PREVIOUSLY TREATED RICHTER TRANSFORMATION: RESULTS FROM THE PHASE 1/2 BRUIN STUDY

Anthony R. Mato - European Hematology Association (EHA) , 2021

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

TREATMENT PATTERNS AND OUTCOMES OF ELDERLY PATIENTS WITH MANTLE CELL LYMPHOMA UNFIT FOR STANDARD IMMUNOCHEMOTHERAPY: A UK AND IRELAND ANALYSIS

Alexandros Rampotas - European Hematology Association (EHA) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Mantle cell lymphoma

Bendamustine

INOTUZUMAB OZOGAMICIN IN RELAPSED OR REFRACTORY ACUTE LYMPHOBLASTIC LEUKAEMIA: A REAL-WORLD RETROSPECTIVE STUDY IN THE UK

David Marks - European Hematology Association (EHA) , 2021

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

Inotuzumab ozogamicin

UPDATED RESULTS FROM PHASE 3 ANDROMEDA STUDY OF PATIENTS WITH NEWLY DIAGNOSED LIGHT CHAIN AMYLOIDOSIS TREATED WITH BORTEZOMIB, CYCLOPHOSPHAMIDE, AND DEXAMETHASONE PLUS SUBCUTANEOUS DARATUMUMAB

Efstathios Kastritis - European Hematology Association (EHA) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

AL Amyloidosis

Cyclophosphamide

Copyright © 2026. QuantiNova All rights reserved